|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,649.65 INR | +0.70% |
|
+0.69% | +3.62% |
| 11/03 | Hester Biosciences Gets Board Nod to Divest 43.8% Stake in Subsidiary; Shares Up 3% | MT |
| 11/03 | Hester Biosciences approves divestment of 43.81% equity in Texas Lifesciences | RE |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 9.26 | 7.07 | 4.26 | 4.05 | 4.33 | |||||
Return on Total Capital | 10.9 | 8.18 | 4.96 | 4.86 | 5.13 | |||||
Return On Equity % | 15.68 | 15.69 | 10.09 | 7.16 | 9.16 | |||||
Return on Common Equity | 16.04 | 16.1 | 9.87 | 6.61 | 9.07 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 75.79 | 73.37 | 70.35 | 67.95 | 70.29 | |||||
SG&A Margin | 21.08 | 20.92 | 24.28 | 24.19 | 23.31 | |||||
EBITDA Margin % | 33.09 | 28.91 | 22.44 | 19.28 | 19.85 | |||||
EBITA Margin % | 27.18 | 22.34 | 15.12 | 13.87 | 14.62 | |||||
EBIT Margin % | 27.16 | 22.32 | 15.11 | 13.86 | 14.6 | |||||
Income From Continuing Operations Margin % | 15.94 | 16.01 | 10.08 | 6.8 | 9.22 | |||||
Net Income Margin % | 15.82 | 15.94 | 9.57 | 6.07 | 8.8 | |||||
Net Avail. For Common Margin % | 15.82 | 15.94 | 9.57 | 6.07 | 8.8 | |||||
Normalized Net Income Margin | 15.21 | 13.46 | 8.51 | 5.44 | 7.49 | |||||
Levered Free Cash Flow Margin | 0.78 | -31.02 | -18.24 | 3.53 | 11.56 | |||||
Unlevered Free Cash Flow Margin | 2.52 | -30.36 | -17.09 | 5.36 | 13.23 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.55 | 0.51 | 0.45 | 0.47 | 0.47 | |||||
Fixed Assets Turnover | 0.95 | 0.88 | 0.77 | 0.77 | 0.76 | |||||
Receivables Turnover (Average Receivables) | 3.98 | 4.5 | 3.94 | 3.85 | 4.1 | |||||
Inventory Turnover (Average Inventory) | 0.84 | 0.95 | 1.03 | 1.24 | 1.27 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.63 | 2.01 | 1.53 | 2.03 | 1.56 | |||||
Quick Ratio | 1.15 | 0.85 | 0.66 | 0.94 | 0.7 | |||||
Operating Cash Flow to Current Liabilities | 0.95 | 0.09 | 0.16 | 0.46 | 0.52 | |||||
Days Sales Outstanding (Average Receivables) | 91.66 | 81.15 | 92.53 | 95.11 | 89.06 | |||||
Days Outstanding Inventory (Average Inventory) | 436.92 | 382.37 | 354.45 | 294.32 | 286.93 | |||||
Average Days Payable Outstanding | 172.28 | 106.73 | 95.3 | 114.07 | 115.11 | |||||
Cash Conversion Cycle (Average Days) | 356.3 | 356.79 | 351.67 | 275.35 | 260.88 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 46.49 | 85.33 | 95.01 | 80.69 | 68.45 | |||||
Total Debt / Total Capital | 31.74 | 46.04 | 48.72 | 44.66 | 40.64 | |||||
LT Debt/Equity | 37.31 | 63.51 | 66.01 | 61.78 | 42.5 | |||||
Long-Term Debt / Total Capital | 25.47 | 34.27 | 33.85 | 34.19 | 25.23 | |||||
Total Liabilities / Total Assets | 42.6 | 52.43 | 56.93 | 54.27 | 50.01 | |||||
EBIT / Interest Expense | 9.75 | 21.37 | 8.16 | 4.73 | 5.47 | |||||
EBITDA / Interest Expense | 11.94 | 27.78 | 12.16 | 6.6 | 7.46 | |||||
(EBITDA - Capex) / Interest Expense | 5.22 | -9.37 | -2.94 | 3.93 | 4.99 | |||||
Total Debt / EBITDA | 1.52 | 3.19 | 4.38 | 4.06 | 3.59 | |||||
Net Debt / EBITDA | 1.22 | 2.84 | 4.14 | 3.81 | 3.48 | |||||
Total Debt / (EBITDA - Capex) | 3.47 | -9.45 | -18.08 | 6.83 | 5.37 | |||||
Net Debt / (EBITDA - Capex) | 2.79 | -8.41 | -17.11 | 6.4 | 5.2 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 15.94 | 13.29 | 12.79 | 11.86 | 0.41 | |||||
Gross Profit, 1 Yr. Growth % | 4.74 | 9.68 | 9.45 | 8.04 | 3.86 | |||||
EBITDA, 1 Yr. Growth % | 19.98 | -1.03 | -12.44 | -3.88 | 3.4 | |||||
EBITA, 1 Yr. Growth % | 26.15 | -6.89 | -23.62 | 2.63 | 5.81 | |||||
EBIT, 1 Yr. Growth % | 26.17 | -6.9 | -23.65 | 2.62 | 5.78 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 11.92 | 13.79 | -29 | -24.5 | 36.19 | |||||
Net Income, 1 Yr. Growth % | 18.03 | 14.2 | -32.28 | -29.06 | 45.52 | |||||
Normalized Net Income, 1 Yr. Growth % | 39.92 | 0.25 | -28.67 | -28.46 | 38.09 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 18.03 | 14.2 | -32.28 | -29.06 | 45.52 | |||||
Accounts Receivable, 1 Yr. Growth % | -15.78 | 12.33 | 44.05 | -1.24 | -6.95 | |||||
Inventory, 1 Yr. Growth % | -2.73 | 21.15 | 12.51 | -10.88 | -6.89 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 11.57 | 31.51 | 27.76 | 0.63 | 0.43 | |||||
Total Assets, 1 Yr. Growth % | 6.32 | 36.76 | 19.18 | -1.14 | -1.35 | |||||
Tangible Book Value, 1 Yr. Growth % | 13.56 | 13.4 | 7.31 | 4 | 6.86 | |||||
Common Equity, 1 Yr. Growth % | 13.55 | 13.87 | 7.59 | 4.31 | 7.7 | |||||
Cash From Operations, 1 Yr. Growth % | 57.87 | -84.83 | 170.84 | 103.99 | 33.89 | |||||
Capital Expenditures, 1 Yr. Growth % | -44.57 | 134.92 | -18.75 | -68.63 | -15.6 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -103.58 | -5.6T | -33.65 | -121.66 | -1.63T | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -112.59 | -1.55T | -36.52 | -135.11 | 1.14T | |||||
Dividend Per Share, 1 Yr. Growth % | 51.52 | 0 | -20 | -25 | 16.67 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 8.72 | 14.61 | 13.05 | 12.33 | 5.98 | |||||
Gross Profit, 2 Yr. CAGR % | 2.94 | 7.18 | 8.92 | 8.74 | 5.93 | |||||
EBITDA, 2 Yr. CAGR % | -1.52 | 8.97 | -6.91 | -8.26 | -0.31 | |||||
EBITA, 2 Yr. CAGR % | -2.8 | 8.38 | -15.67 | -11.47 | 4.21 | |||||
EBIT, 2 Yr. CAGR % | -2.8 | 8.38 | -15.69 | -11.48 | 4.19 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -7.66 | 12.85 | -10.11 | -26.78 | 1.4 | |||||
Net Income, 2 Yr. CAGR % | -8.99 | 16.1 | -12.06 | -30.69 | 1.6 | |||||
Normalized Net Income, 2 Yr. CAGR % | -4.69 | 18.44 | -15.44 | -28.56 | -0.6 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -8.99 | 16.1 | -12.06 | -30.69 | 1.6 | |||||
Accounts Receivable, 2 Yr. CAGR % | 22.37 | -2.74 | 27.21 | 19.28 | -4.14 | |||||
Inventory, 2 Yr. CAGR % | 10.69 | 8.56 | 16.75 | 0.13 | -8.91 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 26.26 | 21.07 | 29.62 | 13.38 | 0.53 | |||||
Total Assets, 2 Yr. CAGR % | 17.16 | 20.59 | 27.67 | 8.55 | -1.25 | |||||
Tangible Book Value, 2 Yr. CAGR % | 13.47 | 13.37 | 10.31 | 5.64 | 5.42 | |||||
Common Equity, 2 Yr. CAGR % | 13.43 | 13.71 | 10.69 | 5.94 | 5.99 | |||||
Cash From Operations, 2 Yr. CAGR % | 11.48 | -51.06 | -36.25 | 135.05 | 65.35 | |||||
Capital Expenditures, 2 Yr. CAGR % | 34.11 | 14.11 | 38.15 | -49.51 | -48.54 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -40.22 | 26.71 | 503.94 | -62.09 | -15.63 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -17.59 | 30.98 | 202.93 | -52.79 | -6.74 | |||||
Dividend Per Share, 2 Yr. CAGR % | -4.65 | 23.09 | -10.56 | -22.54 | -6.46 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 16.6 | 10.22 | 14 | 12.65 | 8.2 | |||||
Gross Profit, 3 Yr. CAGR % | 13.11 | 5.14 | 7.51 | 8.63 | 7.09 | |||||
EBITDA, 3 Yr. CAGR % | 13.36 | -1.36 | 1.31 | -5.91 | -4.53 | |||||
EBITA, 3 Yr. CAGR % | 14.01 | -4.18 | -3.56 | -9.97 | -6.05 | |||||
EBIT, 3 Yr. CAGR % | 14.02 | -4.19 | -3.56 | -9.98 | -6.07 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 14.58 | -1 | -3.3 | -15.19 | -9.96 | |||||
Net Income, 3 Yr. CAGR % | 10.35 | -1.84 | -3 | -18.14 | -11.25 | |||||
Normalized Net Income, 3 Yr. CAGR % | 9.68 | -3.07 | 0.02 | -20.02 | -11.01 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 10.35 | -1.84 | -3 | -18.14 | -11.25 | |||||
Accounts Receivable, 3 Yr. CAGR % | 15.08 | 18.93 | 10.87 | 16.91 | 9.8 | |||||
Inventory, 3 Yr. CAGR % | 16.1 | 14.07 | 9.86 | 6.7 | -2.26 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 19.51 | 27.94 | 23.26 | 19.13 | 8.89 | |||||
Total Assets, 3 Yr. CAGR % | 18.98 | 23.36 | 20.11 | 17.24 | 5.14 | |||||
Tangible Book Value, 3 Yr. CAGR % | 17.64 | 13.38 | 11.31 | 8.17 | 6.04 | |||||
Common Equity, 3 Yr. CAGR % | 17.53 | 13.58 | 11.63 | 8.52 | 6.52 | |||||
Cash From Operations, 3 Yr. CAGR % | 15.15 | -42.66 | -13.75 | -6.05 | 94.91 | |||||
Capital Expenditures, 3 Yr. CAGR % | 21.05 | 61.66 | 1.9 | -15.71 | -40.08 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 5.07 | 152.04 | 2.13 | 99.16 | -22.12 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 82.98 | 109.94 | 2.88 | 47.7 | -17.96 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | -3.13 | 6.62 | -15.66 | -11.21 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 16.63 | 14.88 | 15.17 | 11.06 | 10.72 | |||||
Gross Profit, 5 Yr. CAGR % | 15.77 | 14.25 | 11.41 | 6.31 | 6.87 | |||||
EBITDA, 5 Yr. CAGR % | 16.19 | 11.55 | 4.77 | -4.18 | 0.66 | |||||
EBITA, 5 Yr. CAGR % | 15.88 | 9.88 | 1.05 | -7.17 | -0.52 | |||||
EBIT, 5 Yr. CAGR % | 15.91 | 9.88 | 1.05 | -7.17 | -0.53 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 12.59 | 11.62 | 3.98 | -12.26 | -1.45 | |||||
Net Income, 5 Yr. CAGR % | 12.39 | 10.8 | 0.77 | -14.59 | -1.18 | |||||
Normalized Net Income, 5 Yr. CAGR % | 16.12 | 10.5 | -1.16 | -14.21 | -0.23 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 12.39 | 10.8 | 0.77 | -14.59 | -1.18 | |||||
Accounts Receivable, 5 Yr. CAGR % | 13.4 | 15.81 | 19.79 | 19.07 | 4.6 | |||||
Inventory, 5 Yr. CAGR % | 13.1 | 17.67 | 16.36 | 8.28 | 1.93 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 19.17 | 20.81 | 23.43 | 21.91 | 13.61 | |||||
Total Assets, 5 Yr. CAGR % | 17.21 | 21.44 | 22.38 | 17.21 | 11.07 | |||||
Tangible Book Value, 5 Yr. CAGR % | 17.66 | 16.3 | 14.61 | 10.22 | 8.92 | |||||
Common Equity, 5 Yr. CAGR % | 17.55 | 16.35 | 14.74 | 10.46 | 9.34 | |||||
Cash From Operations, 5 Yr. CAGR % | 25.23 | -24.03 | -9.1 | 0.6 | 11.9 | |||||
Capital Expenditures, 5 Yr. CAGR % | 24 | 25.91 | 27.62 | 1.49 | -22.47 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -25.47 | 185.04 | 103.01 | 18.13 | -5.38 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 0.81 | 99.18 | 121.22 | 15.58 | -1.08 | |||||
Dividend Per Share, 5 Yr. CAGR % | 19.52 | 13.54 | -4.36 | -11.42 | 1.18 |
- Stock Market
- Equities
- 524669 Stock
- Financials Hester Biosciences Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















